Table 1.

Patient and tumor characteristics

Characteristic	Total (n = 58)
Age at diagnosis for lung cancer, average (range)	71 (39–85)
Gender, male/female	25/33
Smoking history, smoker/never smoker	29/29
Pack-years in smokers, average (range)	27 (0.5–144)
Histology, adenocarcinoma/NSCLC	55/3
Type of EGFR mutation, exon19 del/L858R/exon19del + T790M/unknown	27/28/1/2
Clinical stage, III/IV/relapse	6/35/17
Initial EGFR-TKI which induced ILD
Gefitinib	6
Erlotinib*	8
Afatinib*	8
Osimertinib	36
Therapeutic line, 1/2/3/4/5/6th	36/13/2/4/1/2
Response, PR/SD/PD/NE	37/9/1/11

ILD interstitial lung disease, NE not evaluated, PD progressive disease, PR partial response, SD stable disease

*One patient was treated with addition of bevacizumab